Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 20-40 years~* gestational age between 12-30 weeks~* serum HBsAg and HBeAg positivity~* HBV DNA levels \>6log10 copies/mL~* ALT \>1x ULN (40 IU/mL) and \< 10x ULN.~Exclusion Criteria:~* co-infection with hepatitis A, C, D, E or HIV~* evidence of hepatocellular carcinoma; decompensated liver disease or significant renal, cardiovascular, respiratory or neurological co-morbidity~* concurrent treatment with immune-modulators, cytotoxic drugs, or steroids~* clinical signs of threatened miscarriage in early pregnancy~* evidence of fetal deformity by 3-dimensional ultrasound examination~* the biological father of the child had CHB

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: NO_INTERVENTION): None
- telbivudine (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).